← All trials
NCT05659927
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 18, 2022
- Primary completion
- Aug 23, 2023
- Completion date
- Nov 23, 2023
- First posted
- Dec 21, 2022
- Last posted
- Dec 21, 2022
- Enrollment
- 34
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai Mabgeek Biotech.Co.LtdLead sponsor
- Anhui Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.